Content area
Full Text
A 36-year-old woman developed hypersensitivity reaction during treatment with rituximab, and she developed angioedema during treatment with eculizumab for catastrophic antiphospholipid syndrome [CAPS; not all times to reactions onset stated; routes and dosages not stated].
The woman, who had history of systemic lupus erythematosus and antiphospholipid antibody syndrome, presented to hospital with fetal demise...